Literature DB >> 15509505

Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.

Stephanie Laufs1, K Zsuzsanna Nagy, Frank A Giordano, Agnes Hotz-Wagenblatt, W Jens Zeller, Stefan Fruehauf.   

Abstract

Reports on insertional "genotoxicity" in patients have created intense interest in characterizing retroviral vector integrations on the genomic level. The retroviral vector SF91m3 was used for transduction of human peripheral blood progenitor cells (PBPC). These PBPC were transplanted into nonobese diabetic/severe combined immunodeficient mice. A total of 186 retroviral vector integration sites were isolated by ligation-mediated PCR from chimeric mouse bone marrow of five PBPC donors, sequenced, and blasted against the human genome. Preferred integration near the transcription start regions, within CpG islands, and within Alu regions was observed. Detailed analysis of targeted RefSeq genes showed a favored integration within the first intron. Integrations were most common in genes coding for signaling proteins, transcription factors, and kinases. In all genes targeted independently multiple times the respective orientation of the provirus within the gene was identical, indicating integration hot spot regions and similar steric determinants for integration sites. Possible explanations for these findings could be nonrandom vector integration, clonal selection due to gene expression interference, or engraftment issues related to gene insertion in signaling and cell cycle genes. The low frequency of integrations in exons may be reassuring as to the safety of retroviral gene therapy with normal human PBPC.

Entities:  

Mesh:

Year:  2004        PMID: 15509505     DOI: 10.1016/j.ymthe.2004.08.001

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  27 in total

1.  Viral determinants of integration site preferences of simian immunodeficiency virus-based vectors.

Authors:  Hella Monse; Stephanie Laufs; Seraphin Kuate; W Jens Zeller; Stefan Fruehauf; Klaus Uberla
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

2.  Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.

Authors:  Alessandra Recchia; Chiara Bonini; Zulma Magnani; Fabrizia Urbinati; Daniela Sartori; Sara Muraro; Enrico Tagliafico; Attilio Bondanza; Maria Teresa Lupo Stanghellini; Massimo Bernardi; Alessandra Pescarollo; Fabio Ciceri; Claudio Bordignon; Fulvio Mavilio
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

3.  Multiple displacement amplification enables large-scale clonal analysis following retroviral gene therapy.

Authors:  S Bleier; P Maier; H Allgayer; F Wenz; W J Zeller; S Fruehauf; S Laufs
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

4.  Unaltered repopulation properties of mouse hematopoietic stem cells transduced with lentiviral vectors.

Authors:  Africa Gonzalez-Murillo; M Luz Lozano; Eugenio Montini; Juan A Bueren; Guillermo Guenechea
Journal:  Blood       Date:  2008-08-06       Impact factor: 22.113

Review 5.  Gene therapy vectors: the prospects and potentials of the cut-and-paste transposons.

Authors:  Corentin Claeys Bouuaert; Ronald M Chalmers
Journal:  Genetica       Date:  2009-08-02       Impact factor: 1.082

Review 6.  Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies.

Authors:  Perry B Hackett; Elena L Aronovich; David Hunter; Myra Urness; Jason B Bell; Steven J Kass; Laurence J N Cooper; Scott McIvor
Journal:  Curr Gene Ther       Date:  2011-10       Impact factor: 4.391

7.  Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.

Authors:  Sebastian Newrzela; Kerstin Cornils; Tim Heinrich; Julia Schläger; Ji-Hee Yi; Olga Lysenko; Janine Kimpel; Boris Fehse; Dorothee von Laer
Journal:  Mol Med       Date:  2011-07-27       Impact factor: 6.354

Review 8.  The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue.

Authors:  D Gerace; R Martiniello-Wilks; B A O'Brien; A M Simpson
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

Review 9.  Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases.

Authors:  David A Williams; Adrian J Thrasher
Journal:  Stem Cells Transl Med       Date:  2014-03-28       Impact factor: 6.940

10.  Transcription factor binding sites are genetic determinants of retroviral integration in the human genome.

Authors:  Barbara Felice; Claudia Cattoglio; Davide Cittaro; Anna Testa; Annarita Miccio; Giuliana Ferrari; Lucilla Luzi; Alessandra Recchia; Fulvio Mavilio
Journal:  PLoS One       Date:  2009-02-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.